Wayne Anderson, ATS 2021: Targeting the MARCKS Protein in Respiratory Disease

It was a pleasure to meet with Dr Wayne Anderson (UNC School of Medicine, Chapel Hill, NC, US) to discuss his recent study evaluating the safety and tolerability of BIO­‑11006 in patients with acute respiratory distress syndrome.

‘A Phase II, Placebo‑Controlled, Multicenter Pilot Study to Evaluate the Safety and Efficacy of BIO­‑11006 Inhalation Solution in Patients with Acute Respiratory Distress Syndrome.‘ (ABSTRACT NUMBER: A2668) was presented at ATS 2021 International Conference, 14-19 May, 2021.

Questions

1. What is the rationale for targeting the MARCKS protein (myristoylated alanine rich protein kinase C substrate) in respiratory disease? (0:16)
2. Could you tell us a little about BIO-11006, its mechanism of action and the conditions for which it is being investigated? (3:24)

Disclosures: Wayne Anderson has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.

Filmed as a highlight of ATS 2021 (Virtual).